COPD (Chronic Obstructive Pulmonary Disease)

Nothing else matters as much as smoking cessation. Varenicline (Chantix/generic) is the most effective pharmacotherapy — doubles quit rates vs NRT. Bupropion and nicotine replacement therapy are alternatives. Ask your doctor for a prescription — this is medical treatment, not willpower.

COPD is diagnosed by spirometry — an FEV1/FVC ratio <70% post-bronchodilator confirms obstruction. Spirometry stages disease severity (GOLD 1–4) and guides treatment decisions. If you've never had spirometry, get it.

Many COPD patients rely only on short-acting albuterol. This is inadequate maintenance therapy. Long-acting bronchodilators (LAMA + LABA dual therapy, or triple therapy if exacerbations are frequent) are the backbone of COPD treatment. Ask your doctor about Anoro, Stiolto, or similar dual bronchodilator.

Pulmonary rehab provides exercise training, breathing techniques, education, and support. It reduces hospitalizations, improves breathlessness and exercise capacity. Medicare covers pulmonary rehab for eligible patients. The sooner you start, the more lung function and fitness you preserve.

In 2024, Dupixent became the first biologic approved for COPD — for patients with eosinophilic COPD (blood eosinophils ≥300 cells/μL) on triple therapy. If you have frequent exacerbations despite Trelegy or Breztri, ask your pulmonologist to check your blood eosinophil count.

COPD (Chronic Obstructive Pulmonary Disease) is a progressive lung disease that causes permanent narrowing of the airways and destruction of lung tissue (emphysema), making it harder to breathe over time. It's primarily caused by long-term exposure to cigarette smoking (85–90% of cases). COPD covers chronic bronchitis (excessive mucus with chronic cough) and emphysema (destruction of air sacs). Unlike asthma, COPD airflow obstruction is not fully reversible.

GOLD staging classifies COPD severity based on spirometry: GOLD 1 (Mild, FEV1 ≥80%), GOLD 2 (Moderate, FEV1 50–79%), GOLD 3 (Severe, FEV1 30–49%), GOLD 4 (Very Severe, FEV1 <30%). GOLD also categorizes patients as A (low risk, low symptoms), B (low risk, high symptoms), or E (high exacerbation risk). GOLD staging guides treatment decisions — patients with frequent exacerbations typically need triple therapy.

Yes — smoking cessation is the single most important intervention in COPD. It's the only intervention proven to slow the accelerated rate of FEV1 decline. Quitting doesn't reverse existing damage, but dramatically slows progression. Varenicline (Chantix/generic) is the most effective pharmacotherapy. Ask your doctor for a prescription.

Dupixent (dupilumab) was approved by the FDA in 2024 as the first biologic therapy for COPD — specifically for patients with eosinophilic COPD (blood eosinophils ≥300 cells/μL) who remain uncontrolled on triple inhaler therapy. The BOREAS and NOTUS trials showed ~30% reduction in moderate-to-severe COPD exacerbations vs placebo. Eligibility requires blood eosinophil testing.

Absolutely. Pulmonary rehab is one of the most evidence-based interventions in COPD, reducing hospitalizations, improving exercise tolerance, and improving quality of life. Benefits persist for 12–18 months after completing a program. Medicare covers pulmonary rehab for COPD patients with moderate-to-severe disease. Even patients with very severe COPD benefit meaningfully.

COPD inhalers list at $400–$700/month ($5,000–$8,400/year). GSK's COPD copay card (Trelegy, Anoro), AstraZeneca's AZ&Me program (Breztri), and Sanofi's My Dupixent program are all available. NeedyMeds.org and Rx Outreach are options for uninsured patients.